11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      EUS Gastroenterostomy: Primetime for All?

      letter
      , Dr., , Dr., , Prof.
      Endoscopy International Open
      Georg Thieme Verlag KG

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Gastric outlet obstruction (GOO) is a mechanical blockage that clinically progresses based on the degree of obstruction. Patients often experience debilitating symptoms with intractable nausea, vomiting, and limited peroral intake that can quickly lead to malnutrition, decreased quality of life, and potential delays in chemotherapy 1 . While surgical gastroenterostomy (SGE) has been the mainstay of treatment with long-term palliation, it is associated with significant morbidity and mortality that may delay treatment in the postoperative period 2 . Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) has emerged as an effective minimally invasive alternative for suboptimal operative candidates 1 . Comparing these techniques is paramount, especially as increased operator experience with EUS-GE expands and advancements in chemotherapy treatment extends the life expectancy in this patient population. In a recent issue of Endoscopy International Open, Jaruvongvanich et al 3 compare the outcomes of patients undergoing EUS-GE, enteral stenting (ES), or SGE for benign and malignant etiologies of GOO. This was a dual-center retrospective study of 436 patients with a median follow up of 185.5 days, of which 233 were in the EUS-GE cohort. Baseline characteristics between EUS-GE and SGE were largely similar, although the EUS-GE group had higher rates of ascites, peritoneal carcinomatosis, ECOG status, a malignant indication, and symptomatic GOO. The technical success rate was similar in all groups. However, the clinical success rate was significantly higher in the EUS-GE group compared to ES and SGE (98.3% vs 91.6% vs 90.4%, P = 0.002) with lower rates of reintervention (0.9% vs 12.2% vs 13.7%, P < 0.0001) and median length of stay (LOS) (2 vs 3 vs 5 days, P < 0.0001). A subgroup analysis examining the 360 patients with malignant GOO demonstrated similar findings. There were also lower rates of adverse events in the EUS-GE group (8.6%) compared to SGE (27.4%) and ES (38.9%). There were limited instances of stent obstruction, migration, and inadequate stent expansion after EUS-GE. The long-term outcomes of EUS-GE appear to be reliable, especially in a sicker patient population, as was the case in this cohort. This is a well-designed study that advances the current literature supporting the efficacy and durability of EUS-GE, particularly in sick patients. Yet, before these data can alter practice management, one must consider that this study did not differentiate surgical approaches (open and laparoscopic) in their outcomes. Laparoscopic SGE is now the preferred method because it is associated with improved outcomes, decreased LOS, and shorter time to resumption of oral intake 4 . Analyzing outcomes should ideally be done in this context, although such a comparison is limited in a retrospective study. Patients who undergo conversion from laparoscopic to open approaches will likely have fundamentally different outcomes than those whose procedures can be completed laparoscopically. There is selection bias and heterogeneity in all studies to date pertaining to EUS-GE versus SGE. Patients undergoing EUS-GE are generally sicker with more advanced cancers and comorbidities 5 . A more focused comparison between laparoscopic SGE and EUS-GE, therefore, may either blunt or further cement the advantages of a purely endoscopic approach. Prospective studies comparing these techniques are needed as we continue to define the optimal role of EUS-GE for GOO. Publication note Letters to the editor do not necessarily represent the opinion of the editor or publisher. The editor and publisher reserve the right to not publish letters to the editor, or to publish them abbreviated or in extracts.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Endoscopic gastroenterostomy: techniques and review.

          Gastric outlet obstruction (GOO) can result from benign and malignant causes. Until recently, surgical gastrojejunostomy was the treatment of choice for patient with benign and malignant GOO with a good functional status. Endoscopic placement of luminal self-expandable metal stents is currently widely accepted as the first line of treatment for malignant GOO because of its effectiveness and minimally invasive nature. The main shortcoming of luminal stents is the high incidence of recurrent GOO most commonly because of tumor ingrowth/overgrowth. More recently, endoscopic ultrasound (EUS)-guided gastroenterostomy (EUS-GE) has emerged as an alternative to both luminal stent placement and surgical gastrojejunostomy. Advantages of EUS-GE include its minimally invasive nature, efficacy and low incidence of recurrent GOO in cancer patient. We will describe five different techniques to perform this novel and rapidly evolving procedure using a biflanged, lumen-apposing metal stent and compare benefits and risks of each approach. These approaches include antegrade EUS-GE or 'traditional/downstream' and 'rendezvous' methods, retrograde EUS-GE or 'enterogastrostomy,'17 (EPASS), and antegrade EUS-GE 'direct' method.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical outcome and indications for palliative gastrojejunostomy in unresectable advanced gastric cancer: multi-institutional retrospective analysis.

            Palliative gastrojejunostomy (GJJ) for gastric outlet obstruction (GOO) associated with unresectable advanced gastric cancers (UAGC) is the most commonly used treatment modality, but its indication remains controversial. In this multi-institutions study, we investigated the clinical outcome of GJJ for UAGC and predictors of outcome and survival. A retrospective analysis was performed on 211 patients who underwent palliative GJJ for GOO caused by UAGC from 29 institutions between 2007 and 2009. Operative outcome including postoperative morbidity, mortality, assessment of oral intake by GOO Scoring System (GOOSS) and survival time were recorded. Prognostic factors for overall survival and risk factors for hospital death were investigated by univariate and multivariate analyses. Postoperative oral food intake was recorded in 203 (96 %) patients. The average GOOSS improved from 1.1 at baseline to 2.5 at 1 month after surgery and remained above 2 for up to 6 months. Overall morbidity, 30-day mortality and hospital death rates were 22, 6 and 11 %, respectively. Median survival time was 228 days and 1-year survival rate was 31 %. Poor performance status (PS), prior chemotherapy and high C-reactive protein (CRP) level were significant independent predictors of poor survival. Poor PS and high CRP were also identified as significant risk factors of hospital death. Palliative GJJ is beneficial for GOO caused by UAGC in terms of improvement of oral food intake, with acceptable morbidity and mortality. However, its indication for patients with poor PS, high CRP level, and a history of chemotherapy is less clear.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Endoscopic ultrasound-guided gastroenterostomy for the management of gastric outlet obstruction: A large comparative study with long-term follow-up

              Background and study aims  Gastric outlet obstruction (GOO) is traditionally managed with surgical gastroenterostomy (surgical-GE) and enteral stenting (ES). Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is now a third option. Large studies assessing their relative risks and benefits with adequate follow-up are lacking. We conducted a comparative analysis of patients who underwent EUS-GE, ES, or surgical-GE for GOO. Patients and methods  In this retrospective comparative cohort study, consecutive patients presenting with GOO who underwent EUS-GE, ES, or surgical-GE at two academic institutions were reviewed and independently cross-edited to ensure accurate reporting. The primary outcome was need for reintervention. Secondary outcomes were technical and clinical success, length of hospital stay (LOS), and adverse events (AEs). Results  A total of 436 patients (232 EUS-GE, 131 ES, 73 surgical-GE) were included. The median duration of follow-up of the entire cohort was 185.5 days (interquartile range 55.25–454.25 days). The rate of reintervention in the EUS-GE group was lower than in the ES and surgical-GE groups (0.9 %, 12.2 %, and 13.7 %, P  < 0.0001). Technical success was achieved in 98.3 %, 99.2 %, and 100 % ( P  = 0.58), and clinical success was achieved in 98.3 %, 91.6 %, and 90.4 % ( P  < 0.0001) in the EUS-GE, ES, and surgical-GE groups, respectively. The EUS-GE group had a shorter LOS (2 days vs. 3 days vs. 5 days, P  < 0.0001) and a lower AE rate than the ES and surgical-GE groups (8.6 % vs. 38.9 % vs. 27.4 %, P  < 0.0001). Conclusion  This large cohort study demonstrates the safety and palliation durability of EUS-GE as an alternative strategy for GOO palliation in select patients.
                Bookmark

                Author and article information

                Journal
                Endosc Int Open
                Endosc Int Open
                10.1055/s-00025476
                Endoscopy International Open
                Georg Thieme Verlag KG (Rüdigerstraße 14, 70469 Stuttgart, Germany )
                2364-3722
                2196-9736
                09 June 2023
                June 2023
                1 June 2023
                : 11
                : 6
                : E566-E567
                Affiliations
                [1 ]Ringgold 12264, Gastroenterology, University of Maryland School of Medicine, Baltimore, United States;
                [2 ]Ringgold 2331, Gastroenterology, The University of North Carolina at Chapel Hill, Chapel Hill, United States;
                Author notes
                Correspondence Dr. Andrew Canakis Ringgold 12264, Gastroenterology, University of Maryland School of Medicine; BaltimoreUnited States agcanakis@ 123456gmail.com
                Author information
                http://orcid.org/0000-0002-6646-6693
                Article
                EIO-2023-02-2944-LE
                10.1055/a-2090-0533
                10256318
                9dc7fb11-035d-4f37-9144-b4a5432a9f37
                The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

                This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.

                History
                Categories
                Letter to the editor

                Comments

                Comment on this article